Is CGON or CMPX more undervalued in 2026?

CirclFi compares CG Oncology, Inc. (CGON) and Compass Therapeutics, Inc. (CMPX) using 13 institutional-grade valuation models. CGON has a Quality of Company score of 5.0/10 while CMPX scores 5.3/10.

Which is a better buy — CGON or CMPX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CGON and CMPX valuations compare?

CGON at $62.29 and CMPX at $2.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CGON vs CMPX Valuation Comparison 2026 — Intrinsic Value Analysis

CGON

Biological Products, (No Diagnostic Substances)

CG Oncology, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$62.29

Last close

Models

12/13

Active

CMPX

Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

LOW

Price

$2.38

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CGON Fair Value	CGON Upside	CMPX Fair Value	CMPX Upside
Bayesian DCF	Intrinsic	$19.10	-69.3%	$0.66	-72.5%
Earnings Power Value	Intrinsic	$29.69	-56.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.35	-94.9%	$0.18	-90.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CGON vs CMPX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CGON vs CMPX — Which Stock Is More Undervalued?

CMPX scores higher with a 5.3/10 quality rating vs CGON's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CG Oncology, Inc. (CGON) and Compass Therapeutics, Inc. (CMPX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CGON currently trades at $62.29 with a QOC of 5.0/10, while CMPX trades at $2.38 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).